Latest Omeprazole Stories
- Four of the most commonly used proton pump inhibitors raise risk of heart attack and stroke for patients taking Plavix(R) and increase healthcare costs - Drug interaction increases annual hospital costs by nearly 40 percent FRANKLIN LAKES, N.J., May 6 /PRNewswire-FirstCall/ -- Four of the most commonly prescribed heartburn medications reduce the benefit associated with clopidogrel, a widely used antiplatelet medication also known by its brand name, Plavix.
LAS VEGAS, May 6 /PRNewswire/ -- Results of the Clopidogrel Medco Outcomes Study presented today during SCAI's Annual Scientific Sessions found the anti-clotting benefits of clopidogrel (Plavix) may be reduced when taken concurrently with commonly used heartburn medications called proton pump inhibitors (PPIs).
- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer - WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a new drug application (NDA) to the U.S.
In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.
The surprising results of a recent study indicate that the decades long medical practice of prescribing heartburn medications to patients with asthma is ineffective.
Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found
PITTSBURGH, Jan. 23 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S.
-Filing also includes age appropriate formulation of 2.5 mg and 5 mg strengths of NEXIUM for Delayed-Release Oral Suspension- WILMINGTON, Del., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S.
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Wednesday, November 12 at 9:55 a.m. Eastern time (6:55 a.m.
By Chaudhry, A S Kochhar, R; Kohli, K K Proton pump inhibitors (PPIs) are extensively metabolized in the liver by CYP2C19, that demonstrates genetic polymorphism with 21 mutant alleles.
- A handkerchief.
- In general, any miraculous portrait of Christ.